Impact of orphan drugs on Latvian budget

Table 4 Budget impact of orphan drugs in European countries

Country	Budget impact of OD relative to the total drug expenditure	Budget impact of OD (million EUR)	Year	Number of OD with active MA in the EU^a	Population (million)^a [26]	GDP (PPP) per capita^a [31]	OD expenditure per 100 000 inhabitants (EUR)^a
UK	1.0 % [3]	162.0	2007	44	61.32	37 507	264 188
Italy	1.5 % [3]	235.5	2007	44	58.44	33 731	402 977
Spain	2.0 % [3]	256.0	2007	44	45.23	32 807	565 996
Germany	2.1 % [3]	525.0	2007	44	82.27	36 782	638 143
Belgium	1.9 % [16, 17]	66.2	2008	49	10.71	37 847	618 114
Netherlands	4.2 % [12]	260.4	2012	64	16.75	46 379	1 554 627
France	3.1 % [13]	1054.0	2012	64	65.64	37 256	1 605 728
Sweden	2.5 % [13]	107.2	2012	64	9.52	43 869	1 126 050
Latvia	0.84 %	2.64	2014	78	1.99	22 873	132 663

OD orphan drugs, MA marketing authorization, GDP (PPP) per capita gross domestic product per capita based on purchasing power parity
^aIn the year of interest

ISSN: 1750-1172